1974
DOI: 10.1136/bmj.1.5896.11
|View full text |Cite
|
Sign up to set email alerts
|

Effects of a Low-oestrogen Oral Contraceptive on Urinary Excretion of Luteinizing Hormone and Ovarian Steroids

Abstract: SummaryThe urinary gonadotrophin and ovarian steroid excretion pattern was studied in five women taking an oral contraceptive formulation consisting of mestranol 50 jig and norethisterone 1 mg. Both the pretreatment and posttreatment cycles were normal. The ovulatory peak of luteinizing hormone (LH) during the treatment cycles was uniformly suppressed, but LH continued to be excreted within the normal range. In one fifth of the treatment cycles there was a pronounced and sustained rise of oestrogen output in t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
7
0

Year Published

1975
1975
2013
2013

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 32 publications
(7 citation statements)
references
References 9 publications
0
7
0
Order By: Relevance
“…An additional possibility is that chronic changes in estrogen or progesterone levels due to HC use may have directly altered the endogenous opioid system (Foradori et al, 2002; Foradori et al, 2005; Smith et al, 2006), CRF neuron reactivity (Kirschbaum et al, 1996; Kudielka et al, 1998; Thammacharoen et al, 2009), and luteinizing hormone pulsatility (Elstein et al, 1974; Brenner et al, 1977; Mishell et al, 1977; Snowden et al, 1986), each of which are involved in the regulation of the HPA axis and stress response at the level of the hypothalamus, pituitary, and amygdala (Smith et al, 1998; Drolet et al, 2001; Bilkei-Gorzo et al, 2008). Furthermore, there is evidence that estrogens mediate the diurnal rhythm of the HPA axis (Morin et al, 1977; Burgess and Handa 1992; Norman et al, 1992), which may be due to estradiol’s regulation of CRF gene expression (Vamvakopoulos and Chrousos 1993; Roy et al, 1999; Chen et al, 2008; Lalmansingh and Uht 2008; Zhu and Zhou 2008).…”
Section: Discussionmentioning
confidence: 99%
“…An additional possibility is that chronic changes in estrogen or progesterone levels due to HC use may have directly altered the endogenous opioid system (Foradori et al, 2002; Foradori et al, 2005; Smith et al, 2006), CRF neuron reactivity (Kirschbaum et al, 1996; Kudielka et al, 1998; Thammacharoen et al, 2009), and luteinizing hormone pulsatility (Elstein et al, 1974; Brenner et al, 1977; Mishell et al, 1977; Snowden et al, 1986), each of which are involved in the regulation of the HPA axis and stress response at the level of the hypothalamus, pituitary, and amygdala (Smith et al, 1998; Drolet et al, 2001; Bilkei-Gorzo et al, 2008). Furthermore, there is evidence that estrogens mediate the diurnal rhythm of the HPA axis (Morin et al, 1977; Burgess and Handa 1992; Norman et al, 1992), which may be due to estradiol’s regulation of CRF gene expression (Vamvakopoulos and Chrousos 1993; Roy et al, 1999; Chen et al, 2008; Lalmansingh and Uht 2008; Zhu and Zhou 2008).…”
Section: Discussionmentioning
confidence: 99%
“…Residual ovarian activity has been demonstrated in women taking older preparations [3]. Residual ovarian activity has been demonstrated in women taking older preparations [3].…”
Section: Introductionmentioning
confidence: 94%
“…Ovarian follicular development is not completely suppressed during OC use. Ovulatory and anovulatory follicles have been reported in women taking OC (10 -37), and endogenous E 2 levels reportedly attain preovulatory levels (10,15,16,26,31,38,39). The incidence of follicular activity during OC use depends on the type and dose of steroid hormones used in the formulation.…”
mentioning
confidence: 97%